BE2010C018I2 - - Google Patents

Download PDF

Info

Publication number: BE2010C018I2
Authority: BE; Belgium

Application number

BE2010C018C

Other languages

French (fr)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-25

Filing date

2010-04-13

Publication date

2020-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2010C018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-13 Application filed by Novartis Ag filed Critical Novartis Ag

2020-08-20 Publication of BE2010C018I2 publication Critical patent/BE2010C018I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Information Transfer Systems (AREA)
Vehicle Body Suspensions (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Hard Magnetic Materials (AREA)

BE2010C018C 2000-05-25 2010-04-13 BE2010C018I2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20708400P	2000-05-25	2000-05-25
US22892900P	2000-08-30	2000-08-30
PCT/US2001/016863 WO2001089457A2 (en)	2000-05-25	2001-05-24	Thrombopoietin mimetics

Publications (1)

Publication Number	Publication Date
BE2010C018I2 true BE2010C018I2 (en)	2020-08-20

Family

ID=26901947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2010C018C BE2010C018I2 (en)	2000-05-25	2010-04-13

Country Status (30)

Country	Link
US (9)	US7160870B2 (en)
EP (3)	EP1889838B1 (en)
JP (2)	JP3813875B2 (en)
KR (2)	KR100847172B1 (en)
CN (4)	CN101342169A (en)
AR (2)	AR030696A1 (en)
AT (2)	ATE374772T1 (en)
AU (2)	AU2001274938C1 (en)
BE (1)	BE2010C018I2 (en)
BR (1)	BRPI0111116B8 (en)
CA (1)	CA2411468C (en)
CY (4)	CY2010012I2 (en)
CZ (1)	CZ303176B6 (en)
DE (4)	DE122010000037I1 (en)
DK (3)	DK1294378T3 (en)
ES (3)	ES2328179T3 (en)
FR (1)	FR10C0034I2 (en)
HK (4)	HK1113057A1 (en)
HU (3)	HU230487B1 (en)
IL (5)	IL152988A0 (en)
LU (1)	LU91681I2 (en)
MX (1)	MXPA02011621A (en)
MY (1)	MY136707A (en)
NO (3)	NO324246B1 (en)
NZ (2)	NZ522474A (en)
PL (2)	PL218617B1 (en)
PT (3)	PT1889838E (en)
SI (3)	SI1864981T1 (en)
TW (1)	TWI305207B (en)
WO (1)	WO2001089457A2 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1516705A (en) *	2000-03-08	2004-07-28	֢��ƹ�˾	Novel aryl fructose-1,6-bisphosphatase inhibitors
US20110212054A1 (en) *	2000-05-25	2011-09-01	Glaxosmithkline Llc.	Thrombopoietin mimetics
CY2010012I2 (en) *	2000-05-25	2020-05-29	Novartis Ag	THROMBOPOIETIN MIMETICS
EP1370252A4 (en) *	2001-03-01	2006-04-05	Smithkline Beecham Corp	Thrombopoietin mimetics
US7659409B2 (en)	2002-03-19	2010-02-09	Mitsubishi Chemical Corporation	3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
MY142390A (en)	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en) *	2002-06-06	2003-12-18	Smithkline Beecham Corporation	Thrombopoietin mimetics
CA2495184A1 (en)	2002-08-14	2004-02-26	Nissan Chemical Industries, Ltd.	Thrombopoietin receptor activators and process for their production
TWI324593B (en)	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
US20090048318A1 (en) *	2003-04-29	2009-02-19	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US20070105824A1 (en) *	2003-04-29	2007-05-10	Erickson-Miller Connie L	Methods for treating degenerative diseases/injuries
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
US20090143453A1 (en) *	2003-04-29	2009-06-04	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US20100004302A1 (en) *	2003-04-29	2010-01-07	Connie Erickson-Miller	Methods for Treating Degenerative Diseases/Injuries
US7753958B2 (en) *	2003-08-05	2010-07-13	Gordon Charles R	Expandable intervertebral implant
SE0302486D0 (en) *	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
TW200526638A (en) *	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en)	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Thrombopoietin activity modulating compounds and methods
WO2006034473A2 (en) *	2004-09-23	2006-03-30	Reddy Us Therapeutics, Inc.	Novel pyrimidine compounds, process for their preparation and compositions containing them
AU2005299720B2 (en) *	2004-10-25	2010-02-04	Ligand Pharmaceuticals Incorporated	Thrombopoietin activity modulating compounds and methods
US8552031B2 (en)	2004-12-08	2013-10-08	Nissan Chemical Industries, Ltd.	3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
JP4973192B2 (en)	2004-12-14	2012-07-11	日産化学工業株式会社	Amide compound and thrombopoietin receptor activator
TW200716580A (en)	2005-06-08	2007-05-01	Smithkline Beecham Corp	(5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
EP1904472A1 (en)	2005-07-15	2008-04-02	Nissan Chemical Industries, Ltd.	Thiophene compounds and thrombopoietin receptor activators
WO2007011056A1 (en)	2005-07-20	2007-01-25	Nissan Chemical Industries, Ltd.	Pyrazole compounds and thrombopoietin receptor activators
WO2007044982A2 (en) *	2005-10-13	2007-04-19	Smithkline Beecham Corporation	Methods for the preservation of platelet efficacy during storage
WO2007052808A1 (en)	2005-11-07	2007-05-10	Nissan Chemical Industries, Ltd.	Hydrazide compound and thrombopoietin receptor activator
WO2007142308A1 (en)	2006-06-07	2007-12-13	Nissan Chemical Industries, Ltd.	Nitrogen-containing heterocyclic compound and thrombopoietin receptor activator
US7786159B2 (en) *	2006-12-01	2010-08-31	Stategics, Inc.	Thrombopoietin mimetics
US20110160130A1 (en) *	2007-02-16	2011-06-30	Connie Erickson-Miller	Cancer treatment method
UY30915A1 (en) *	2007-02-16	2008-09-02	Smithkline Beecham Corp	CANCER TREATMENT METHOD
US20110129550A1 (en) *	2007-02-16	2011-06-02	Connie Erickson-Miller	Cancer treatment method
EP2152811A4 (en) *	2007-04-24	2011-03-16	Glaxosmithkline Llc	Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics
ECSP077628A (en)	2007-05-03	2008-12-30	Smithkline Beechman Corp	NEW PHARMACEUTICAL COMPOSITION
CA2709224C (en) *	2007-10-09	2015-06-23	The Trustees Of The University Of Pennsylvania	Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
CN101481352A (en) *	2008-01-10	2009-07-15	上海恒瑞医药有限公司	Bicycle substituted pyrazolone azo derivative, preparation thereof and use in medicine
US8236838B2 (en)	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en)	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
WO2009151862A1 (en) *	2008-05-15	2009-12-17	Smithkline Beecham Corporation	Method of treatment
EP2348858A4 (en) *	2008-10-16	2013-06-12	Glaxosmithkline Llc	Method of treating thrombocytopenia
PE20100362A1 (en)	2008-10-30	2010-05-27	Irm Llc	PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
WO2010114943A1 (en) *	2009-04-01	2010-10-07	Pliva Hrvatska D.O.O.	Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
US8476249B2 (en)	2009-05-07	2013-07-02	Glaxosmithkline Llc	Method of treating thrombocytopenia
WO2010129738A1 (en) *	2009-05-07	2010-11-11	Glaxosmithkline Llc	Method of treating thrombocytopenia
US8680150B2 (en) *	2009-05-28	2014-03-25	Ligand Pharmaceuticals, Inc.	Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
KR20120015355A (en) *	2009-05-29	2012-02-21	글락소스미스클라인 엘엘씨	Methods of administration of thrombopoietin agonist compounds
CN101921232A (en) *	2009-06-11	2010-12-22	上海恒瑞医药有限公司	Salt of 2-ring substituted pyrazolone azo derivatives, and preparation method and application thereof in medicaments
CA2782010A1 (en)	2009-12-01	2011-06-09	Basf Se	Polyurethane-based pultrusion resin system
CN101805291A (en) *	2010-04-26	2010-08-18	西北大学	1-(4-isopropylbenzene-yl)-3-methyl-5-pyrazolone, preparation method and application thereof
CA2808908A1 (en)	2010-09-01	2012-03-08	Novartis Ag	Combination of hdac inhibitors with thrombocytopenia drugs
WO2012102937A2 (en)	2011-01-25	2012-08-02	Irm Llc	Compounds that expand hematopoietic stem cells
WO2012121957A1 (en) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Combination
WO2012121958A2 (en) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Combination
US20120309796A1 (en)	2011-06-06	2012-12-06	Fariborz Firooznia	Benzocycloheptene acetic acids
EP2729560A4 (en) *	2011-07-06	2014-12-03	Cellerant Therapeutics Inc	Megakaryocyte progenitor cells for production of platelets
PT2750677T (en) *	2011-08-30	2017-07-03	Chdi Foundation Inc	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755955A4 (en)	2011-09-13	2015-08-19	Glenmark Generics Ltd	Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds
WO2013049605A1 (en)	2011-09-28	2013-04-04	Assia Chemical Industries Ltd.	Processes for the preparation of an intermediate in the synthesis of eltrombopag
EP2766355B1 (en)	2011-10-11	2020-12-23	Dana-Farber Cancer Institute, Inc.	Pyrazol-3-ones that activate pro-apoptotic bax
JP6072058B2 (en)	2011-11-14	2017-02-01	リガンド・ファーマシューティカルズ・インコーポレイテッド	Methods and compositions for binding to granulocyte colony stimulating factor receptor
AU2012347534B2 (en)	2011-12-08	2018-01-25	Fred Hutchinson Cancer Research Center	Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
DK2807165T3 (en)	2012-01-27	2019-07-15	Univ Montreal	PYRIMIDO [4,5-B] INDOL DERIVATIVES AND USE THEREOF IN EXPANSION OF HEMATOPOITIC STUDY CELLS
CN103360317B (en) *	2012-04-11	2016-12-14	齐鲁制药有限公司	Bicycle substituted pyrazolone azo analog derivative, Preparation Method And The Use
JP2015154715A (en) *	2012-05-22	2015-08-27	国立大学法人旭川医科大学	Novel revascularization cell population derived from human monocyte and differentiation inducing method thereof
US20140047572A1 (en) *	2012-08-13	2014-02-13	University Of Rochester	Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2014150252A1 (en)	2013-03-15	2014-09-25	Ligand Pharmaceuticals Incorporated	Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP2799425A1 (en)	2013-04-29	2014-11-05	Esteve Química, S.A.	Preparation process of an agonist of the thrombopoietin receptor
US9770437B2 (en)	2013-09-02	2017-09-26	Hetero Research Foundation	Compositions of eltrombopag
ITMI20131782A1 (en) *	2013-10-25	2015-04-26	Dipharma Francis Srl	PROCEDURE FOR THE PREPARATION OF A TROMBOPOIETIN AGONIST
CN104628647A (en) *	2013-11-12	2015-05-20	上海医药工业研究院	Preparation method of 3-methyl-1-(3,4-dimethylphenyl)-2-pyrazoline-5-one
CN104725318A (en) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	Synthetic method of eltrombopag olamine
WO2015111085A2 (en)	2014-01-27	2015-07-30	Cadila Healthcare Limited	Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN103819406B (en) *	2014-03-17	2015-04-08	苏州明锐医药科技有限公司	Preparation method of eltrombopag olamine
CN111620870B (en)	2014-04-22	2023-01-03	蒙特利尔大学	Compound and application thereof in expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
CN105085287A (en) *	2014-05-12	2015-11-25	上海医药工业研究院	Preparation method of 3'-amino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
CN105085276A (en) *	2014-05-12	2015-11-25	上海医药工业研究院	Eltrombopag intermediate and preparation method therefor and application thereof
UA120856C2 (en)	2014-07-17	2020-02-25	Кхді Фаундейшн, Інк.	Methods and compositions for treating hiv-related disorders
EP3188737A4 (en)	2014-09-05	2018-05-02	Hetero Research Foundation	Crystalline form of eltrombopag free acid
WO2016055935A1 (en)	2014-10-06	2016-04-14	Glaxosmithkline Intellectual Property (No.2) Limited	Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
CA2966150A1 (en)	2014-10-31	2016-05-06	Nissan Chemical Industries, Ltd.	Ligand-binding fiber and cell culture substrate using said fiber
CN104829593B (en) *	2015-03-26	2017-08-25	苏州福来兹检测科技有限公司	A kind of organic compound and its application for being used to detect metal ion in solution content
WO2017042839A1 (en)	2015-09-08	2017-03-16	Actavis Group Ptc Ehf.	Novel eltrombopag salt and preparation thereof
US11142616B2 (en)	2016-04-21	2021-10-12	Basf Se	Method for producing pultruded products on the basis of polyurethane
EP3474834A1 (en)	2016-06-27	2019-05-01	The General Hospital Corporation Dba Massachusetts General Hospital	Stimulating platelet generation by activating mitochondrial biogenesis
CN110382580B (en)	2017-03-09	2022-04-19	巴斯夫欧洲公司	Polyurethane formulation for producing composite elements
CN107021928B (en) *	2017-04-01	2022-11-18	常州制药厂有限公司	Eltrombopag intermediate, preparation method and application thereof
EP3395331B1 (en)	2017-04-26	2019-08-21	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical tablet composition comprising eltrombopag olamine
WO2019071111A1 (en)	2017-10-06	2019-04-11	Teva Pharmaceuticals Usa, Inc.	Solid state forms of eltrombopag choline
EP3409272B1 (en)	2018-03-07	2020-06-24	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
CN110467531B (en) *	2018-05-09	2022-04-19	新发药业有限公司	Preparation method of 3 '-nitro-2' -hydroxybiphenyl-3-formic acid
WO2019229572A1 (en) *	2018-06-01	2019-12-05	Aurobindo Pharma Ltd	An improved process for the preparation of eltrombopag olamine and its intermediates
EP3604284B1 (en)	2018-08-02	2020-11-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Crystalline eltrombopag monoethanolamine salt form d
EP3604285B1 (en)	2018-08-02	2020-06-17	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Highly stable crystalline form d1 of the eltrombopag monoethanolamine salt
TW202042806A (en) *	2019-01-08	2020-12-01	大陸商江蘇恒瑞醫藥股份有限公司	Dosing regimens for bicyclic substituted pyrazolone azo derivatives
EP3994126A1 (en)	2019-07-04	2022-05-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Process for the preparation of key intermediates for the synthesis of eltrombopag or salt thereof
JP7083793B2 (en) *	2019-09-10	2022-06-13	Ｊｆｅケミカル株式会社	Method for producing paraterphenyltetracarboxylic acid and paraterphenyltetracarboxylic acid dianhydride
WO2021055820A1 (en)	2019-09-20	2021-03-25	Novartis Ag	3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
WO2021078077A1 (en) *	2019-10-21	2021-04-29	广东东阳光药业有限公司	New crystal form of acetylated eltrombopag and preparation method therefor
CN114341112A (en) *	2019-10-21	2022-04-12	广东东阳光药业有限公司	Novel crystal form of acetylated eltrombopag and preparation method thereof
AU2020397233A1 (en)	2019-12-06	2022-06-30	Synthon B.V.	Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
US20230025286A1 (en)	2019-12-06	2023-01-26	Synthon B.V.	Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
TR202014694A1 (en)	2020-09-16	2022-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	ELTROMBOPAG A SOLID ORAL PHARMACEUTICAL FORMULATION CONTAINING OLAMINE
WO2022201087A1 (en)	2021-03-25	2022-09-29	Novartis Ag	3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN113336704B (en) *	2021-06-11	2022-10-11	上海大学	Danshensu derivative and preparation method and medical application thereof
CN114507186A (en) *	2021-12-02	2022-05-17	天津力生制药股份有限公司	Preparation method of eltrombopag
EP4436554A1 (en)	2021-12-15	2024-10-02	Galenicum Health SLU	Pharmaceutical compositions comprising eltrombopag

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE193350C (en)
US851444A (en) *	1905-11-13	1907-04-23	Agfa Ag	Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en)	1953-02-27	1957-07-24	Ciba Ltd	Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) *	1954-10-26	1957-10-15	Ciba Ltd	Azo-dyestuffs
DE1046220B (en) *	1956-04-21	1958-12-11	Bayer Ag	Process for the production of monoazo dyes and their metal complex compounds
GB826207A (en)	1956-07-23	1959-12-31	Bayer Ag	ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) *	1956-11-20	1960-08-23	Agfa Ag	Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) *	1965-04-09	1968-01-30	Interchem Corp	Disazo pyrazolone pigments
US4435417A (en) *	1981-02-20	1984-03-06	Gruppo Lepetit S.P.A.	Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES8503669A1 (en) *	1982-07-05	1985-03-01	Erba Farmitalia	N-Imidazolyl derivatives containing naphthalene or indene nucleus
FR2559483B1 (en) *	1984-02-10	1986-12-05	Sandoz Sa	HETEROCYCLIC COMPOUNDS CONTAINING BASIC AND / OR CATIONIC GROUPS, THEIR PREPARATION AND THEIR USE AS DYES
FI91869C (en) *	1987-03-18	1994-08-25	Tanabe Seiyaku Co	Process for the preparation of benzoxazole derivatives as antidiabetic agents
US4880788A (en) *	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
US5326776A (en) *	1992-03-02	1994-07-05	Abbott Laboratories	Angiotensin II receptor antagonists
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (en)	1993-08-13	1995-02-15	Ciba-Geigy Ag	Pigment salts
DE69423661T2 (en) *	1993-12-28	2000-11-23	Dai Nippon Printing Co., Ltd.	Thermal transfer recording layer using a specific dye
SG47030A1 (en) *	1994-01-03	1998-03-20	Genentech Inc	Thrombopoietin
JPH09508797A (en)	1994-02-14	1997-09-09	ザイモジェネティクス，インコーポレイティド	Hematopoietic proteins and materials and methods for producing same
US5482546A (en) *	1994-03-30	1996-01-09	Canon Kabushiki Kaisha	Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en)	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en)	1995-02-13	1998-05-05	Engelhard Corporation	Pigment compositions
EP1961760A3 (en)	1995-06-07	2008-09-03	Glaxo Group Limited	Peptides and compounds that bind to a thrombopoietin receptor
US5622818A (en) *	1995-11-29	1997-04-22	Eastman Kodak Company	Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) *	1996-05-30	1997-09-23	Engelhard Corporation	Pigment compositions
US5932546A (en) *	1996-10-04	1999-08-03	Glaxo Wellcome Inc.	Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (en)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
GB9715830D0 (en)	1997-07-25	1997-10-01	Basf Ag	Reactive dyes containing piperazine
WO1999011262A1 (en)	1997-09-02	1999-03-11	Roche Diagnostics Gmbh	Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
DE69837279T2 (en) *	1997-10-31	2007-11-15	Smithkline Beecham Corp.	NEW METAL COMPLEXES
DE19851389A1 (en) *	1998-11-07	2000-05-11	Dystar Textilfarben Gmbh & Co	Yellow dye mixtures of water-soluble fiber-reactive azo dyes and their use
GC0000177A (en) *	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
US6750342B1 (en)	1999-05-19	2004-06-15	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
CN1376150A (en)	1999-07-26	2002-10-23	盐野义制药株式会社	Drug compositions exhibiting thrombo poietin agonism
EP1213965B1 (en)	1999-09-10	2006-01-18	Smithkline Beecham Corporation	Thrombopoietin mimetics
JP2003509462A (en)	1999-09-24	2003-03-11	スミスクライン・ビーチャム・コーポレイション	Thrombopoietin mimic
JP2003513965A (en)	1999-11-05	2003-04-15	スミスクライン・ビーチャム・コーポレイション	Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2160560T1 (en)	1999-11-10	2001-11-16	Curacyte Ag	COLORS OR, O'-DIHIDROXI-AZOIC AS CONSTITUENTS OF MEDICINES FOR THE TREATMENT OF TROMBOPENIAS.
TWI284639B (en)	2000-01-24	2007-08-01	Shionogi & Co	A compound having thrombopoietin receptor agonistic effect
MY133845A (en)	2000-03-10	2007-11-30	Smithkline Beecham Corp	Il-8 receptor antagonists
US6214813B1 (en) *	2000-04-07	2001-04-10	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6436915B1 (en) *	2000-04-07	2002-08-20	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
CY2010012I2 (en) *	2000-05-25	2020-05-29	Novartis Ag	THROMBOPOIETIN MIMETICS
US6642265B1 (en) *	2000-09-08	2003-11-04	Smithkline Beecham Corporation	Thrombopoietin mimetics
WO2002049413A2 (en)	2000-12-19	2002-06-27	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1351979B1 (en)	2000-12-21	2008-01-16	Smithkline Beecham Corporation	Regulated activation of cell-membrane receptors by metal-chelating agonists
CN1516696A (en)	2001-01-26	2004-07-28	盐野义制药株式会社	Halogen compounds having thrombopoietin receptor agonism
WO2002059099A1 (en)	2001-01-26	2002-08-01	Shionogi & Co., Ltd.	Cyclic compounds having thrombopoietin receptor agonism
EP1370252A4 (en)	2001-03-01	2006-04-05	Smithkline Beecham Corp	Thrombopoietin mimetics
JP3927001B2 (en)	2001-06-15	2007-06-06	三菱化学株式会社	Dye set, ink set and recording method
US6560161B1 (en) *	2001-08-30	2003-05-06	Micron Technology, Inc.	Synchronous flash memory command sequence
AU2002333114B2 (en)	2001-11-30	2008-09-04	Qlt Inc.	Hydrazonopyrazole derivatives and their use as therapeutics
WO2003074550A2 (en)	2002-03-01	2003-09-12	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
MY142390A (en)	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en)	2002-06-06	2003-12-18	Smithkline Beecham Corporation	Thrombopoietin mimetics
TWI324593B (en) *	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
AU2003297925A1 (en)	2002-12-13	2004-07-09	Smithkline Beecham Corporation	Thrombopoietin mimetics
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
US20070105824A1 (en) *	2003-04-29	2007-05-10	Erickson-Miller Connie L	Methods for treating degenerative diseases/injuries
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) *	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Thrombopoietin activity modulating compounds and methods
AU2005299720B2 (en) *	2004-10-25	2010-02-04	Ligand Pharmaceuticals Incorporated	Thrombopoietin activity modulating compounds and methods
WO2007044982A2 (en) *	2005-10-13	2007-04-19	Smithkline Beecham Corporation	Methods for the preservation of platelet efficacy during storage
US7786159B2 (en) *	2006-12-01	2010-08-31	Stategics, Inc.	Thrombopoietin mimetics

2000
- 2000-06-03 CY CY2010012C patent/CY2010012I2/en unknown
2001
- 2001-05-23 TW TW090112317A patent/TWI305207B/en active
- 2001-05-23 MY MYPI20012430A patent/MY136707A/en unknown
- 2001-05-23 AR ARP010102468A patent/AR030696A1/en active IP Right Grant
- 2001-05-24 DE DE122010000037C patent/DE122010000037I1/en active Pending
- 2001-05-24 AU AU2001274938A patent/AU2001274938C1/en active Active
- 2001-05-24 DK DK01941599T patent/DK1294378T3/en active
- 2001-05-24 HU HU0800710A patent/HU230487B1/en not_active IP Right Cessation
- 2001-05-24 KR KR1020077018036A patent/KR100847172B1/en active IP Right Review Request
- 2001-05-24 NZ NZ522474A patent/NZ522474A/en not_active IP Right Cessation
- 2001-05-24 AU AU7493801A patent/AU7493801A/en active Pending
- 2001-05-24 MX MXPA02011621A patent/MXPA02011621A/en active IP Right Grant
- 2001-05-24 PT PT07112106T patent/PT1889838E/en unknown
- 2001-05-24 DK DK07112105T patent/DK1864981T3/en active
- 2001-05-24 IL IL15298801A patent/IL152988A0/en active IP Right Grant
- 2001-05-24 HU HU0800310A patent/HU230387B1/en not_active IP Right Cessation
- 2001-05-24 EP EP07112106A patent/EP1889838B1/en not_active Expired - Lifetime
- 2001-05-24 CN CNA2008101297607A patent/CN101342169A/en active Pending
- 2001-05-24 KR KR1020027015869A patent/KR100798568B1/en active Protection Beyond IP Right Term
- 2001-05-24 BR BRPI0111116A patent/BRPI0111116B8/en not_active IP Right Cessation
- 2001-05-24 CN CNB018133401A patent/CN100423721C/en not_active Expired - Lifetime
- 2001-05-24 PT PT07112105T patent/PT1864981E/en unknown
- 2001-05-24 SI SI200130938T patent/SI1864981T1/en unknown
- 2001-05-24 CN CN2008101297594A patent/CN101343251B/en not_active Expired - Fee Related
- 2001-05-24 ES ES07112105T patent/ES2328179T3/en not_active Expired - Lifetime
- 2001-05-24 AT AT01941599T patent/ATE374772T1/en active
- 2001-05-24 NZ NZ533308A patent/NZ533308A/en not_active IP Right Cessation
- 2001-05-24 PL PL393259A patent/PL218617B1/en unknown
- 2001-05-24 HU HU0302257A patent/HU227476B1/en active Protection Beyond IP Right Term
- 2001-05-24 US US10/296,688 patent/US7160870B2/en not_active Expired - Lifetime
- 2001-05-24 CA CA002411468A patent/CA2411468C/en not_active Expired - Lifetime
- 2001-05-24 CN CN200810129758XA patent/CN101343250B/en not_active Expired - Fee Related
- 2001-05-24 DK DK07112106.5T patent/DK1889838T3/en active
- 2001-05-24 DE DE60139354T patent/DE60139354D1/en not_active Expired - Lifetime
- 2001-05-24 CZ CZ20023852A patent/CZ303176B6/en unknown
- 2001-05-24 EP EP07112105A patent/EP1864981B8/en not_active Expired - Lifetime
- 2001-05-24 JP JP2001585703A patent/JP3813875B2/en not_active Expired - Lifetime
- 2001-05-24 PL PL359270A patent/PL216528B1/en unknown
- 2001-05-24 SI SI200130955T patent/SI1889838T1/en unknown
- 2001-05-24 DE DE60130760T patent/DE60130760T2/en not_active Expired - Lifetime
- 2001-05-24 AT AT07112106T patent/ATE445606T1/en active
- 2001-05-24 DE DE60140224T patent/DE60140224D1/en not_active Expired - Lifetime
- 2001-05-24 EP EP01941599A patent/EP1294378B1/en not_active Expired - Lifetime
- 2001-05-24 ES ES01941599T patent/ES2294000T3/en not_active Expired - Lifetime
- 2001-05-24 SI SI200130790T patent/SI1294378T1/en unknown
- 2001-05-24 WO PCT/US2001/016863 patent/WO2001089457A2/en active Application Filing
- 2001-05-24 ES ES07112106T patent/ES2334843T3/en not_active Expired - Lifetime
- 2001-05-24 PT PT01941599T patent/PT1294378E/en unknown
2002
- 2002-11-20 IL IL152988A patent/IL152988A/en active Protection Beyond IP Right Term
- 2002-11-20 NO NO20025566A patent/NO324246B1/en active Protection Beyond IP Right Term
2003
- 2003-09-09 HK HK08103330.5A patent/HK1113057A1/en not_active IP Right Cessation
- 2003-09-09 HK HK03106428A patent/HK1055561A1/en not_active IP Right Cessation
- 2003-09-19 HK HK03106754.0A patent/HK1056114A1/en unknown
2005
- 2005-12-07 JP JP2005353686A patent/JP4546919B2/en not_active Expired - Fee Related
2006
- 2006-11-09 US US11/558,071 patent/US7335649B2/en not_active Expired - Fee Related
2007
- 2007-01-05 US US11/620,260 patent/US7332481B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,651 patent/US7473686B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,688 patent/US7439342B2/en not_active Expired - Fee Related
- 2007-01-08 US US11/650,838 patent/US7452874B2/en not_active Expired - Lifetime
- 2007-12-13 CY CY20071101583T patent/CY1107087T1/en unknown
2008
- 2008-04-10 HK HK08104080.5A patent/HK1117825A1/en not_active IP Right Cessation
- 2008-05-02 AR ARP080101867A patent/AR066036A2/en active IP Right Grant
- 2008-06-18 US US12/141,379 patent/US7674887B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,422 patent/US7648971B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,397 patent/US7790704B2/en not_active Expired - Fee Related
- 2008-08-21 IL IL193617A patent/IL193617A/en not_active IP Right Cessation
- 2008-08-21 IL IL193618A patent/IL193618A0/en not_active IP Right Cessation
- 2008-08-21 IL IL193619A patent/IL193619A0/en unknown
2009
- 2009-08-13 CY CY20091100873T patent/CY1109435T1/en unknown
2010
- 2010-01-11 CY CY20101100027T patent/CY1109730T1/en unknown
- 2010-04-13 BE BE2010C018C patent/BE2010C018I2/fr unknown
- 2010-04-21 LU LU91681C patent/LU91681I2/en unknown
- 2010-06-18 FR FR10C0034C patent/FR10C0034I2/en active Active
- 2010-08-19 NO NO2010017C patent/NO2010017I2/en unknown
2020
- 2020-11-19 NO NO2020040C patent/NO2020040I1/en unknown

Also Published As

Publication number	Publication date
CY1109435T1 (en)	2014-08-13
CN101343250B (en)	2011-09-21
DE60130760T2 (en)	2008-07-17
EP1294378B1 (en)	2007-10-03
JP4546919B2 (en)	2010-09-22
ATE445606T1 (en)	2009-10-15
SI1864981T1 (en)	2009-12-31
US20080090996A1 (en)	2008-04-17
DE122010000037I1 (en)	2011-01-27
EP1889838A1 (en)	2008-02-20
DK1864981T3 (en)	2009-09-07
ES2334843T3 (en)	2010-03-16
CN100423721C (en)	2008-10-08
AR066036A2 (en)	2009-07-22
BR0111116A (en)	2003-04-08
TWI305207B (en)	2009-01-11
PT1889838E (en)	2010-01-19
EP1864981B1 (en)	2009-07-22
CY2010012I2 (en)	2020-05-29
JP2003534257A (en)	2003-11-18
HUP0302257A2 (en)	2003-10-28
IL193617A0 (en)	2009-02-11
WO2001089457A3 (en)	2002-03-07
IL193617A (en)	2013-06-27
US20090176973A1 (en)	2009-07-09
US7160870B2 (en)	2007-01-09
DE60139354D1 (en)	2009-09-03
HU230487B1 (en)	2016-08-29
US20070179192A1 (en)	2007-08-02
KR20030060773A (en)	2003-07-16
WO2001089457A2 (en)	2001-11-29
CA2411468C (en)	2008-04-15
AU2001274938C1 (en)	2006-09-28
HU0800710D0 (en)	2009-01-28
AR030696A1 (en)	2003-09-03
CN101343251A (en)	2009-01-14
HU0800310D0 (en)	2008-07-28
US20080214640A1 (en)	2008-09-04
PL359270A1 (en)	2004-08-23
IL152988A0 (en)	2003-06-24
US7332481B2 (en)	2008-02-19
PT1294378E (en)	2008-01-09
KR20070087255A (en)	2007-08-27
EP1294378A4 (en)	2004-01-28
HUP0800710A2 (en)	2003-10-28
BRPI0111116B8 (en)	2021-05-25
MY136707A (en)	2008-11-28
KR100798568B1 (en)	2008-01-28
HK1056114A1 (en)	2004-02-06
ES2294000T3 (en)	2008-04-01
HU227476B1 (en)	2011-07-28
HK1055561A1 (en)	2004-01-16
SI1294378T1 (en)	2008-02-29
LU91681I9 (en)	2019-01-03
NZ522474A (en)	2004-10-29
US7439342B2 (en)	2008-10-21
DE60130760D1 (en)	2007-11-15
US7790704B2 (en)	2010-09-07
CY1107087T1 (en)	2012-01-25
ES2328179T3 (en)	2009-11-10
IL193618A0 (en)	2009-02-11
HK1117825A1 (en)	2009-01-23
AU2001274938B2 (en)	2006-01-19
PL218617B1 (en)	2015-01-30
IL152988A (en)	2009-02-11
US20090155203A1 (en)	2009-06-18
KR100847172B1 (en)	2008-07-17
EP1889838B1 (en)	2009-10-14
EP1864981B8 (en)	2009-11-11
US7674887B2 (en)	2010-03-09
US7473686B2 (en)	2009-01-06
US20090176746A1 (en)	2009-07-09
NO324246B1 (en)	2007-09-17
CN101342169A (en)	2009-01-14
CN1444477A (en)	2003-09-24
CY2010012I1 (en)	2012-01-25
DK1294378T3 (en)	2008-01-28
US20080090787A1 (en)	2008-04-17
FR10C0034I2 (en)	2011-04-29
CN101343251B (en)	2011-11-09
NO2010017I2 (en)	2012-06-11
CA2411468A1 (en)	2001-11-29
CZ303176B6 (en)	2012-05-16
DK1889838T3 (en)	2010-02-08
HUP0302257A3 (en)	2007-03-28
US20070129338A1 (en)	2007-06-07
ATE374772T1 (en)	2007-10-15
PL393259A1 (en)	2011-07-04
SI1889838T1 (en)	2010-02-26
EP1864981A1 (en)	2007-12-12
BR0111116B1 (en)	2013-10-08
NZ533308A (en)	2005-10-28
JP3813875B2 (en)	2006-08-23
LU91681I2 (en)	2010-06-21
HU230387B1 (en)	2016-03-29
NO2010017I1 (en)	2010-09-20
US7648971B2 (en)	2010-01-19
CY1109730T1 (en)	2014-09-10
DE60140224D1 (en)	2009-11-26
FR10C0034I1 (en)	2010-06-08
NO20025566D0 (en)	2002-11-20
NO20025566L (en)	2003-01-22
PL216528B1 (en)	2014-04-30
NO2020040I1 (en)	2020-11-19
CN101343250A (en)	2009-01-14
US7452874B2 (en)	2008-11-18
AU7493801A (en)	2001-12-03
US7335649B2 (en)	2008-02-26
PT1864981E (en)	2009-08-31
CZ20023852A3 (en)	2003-05-14
EP1294378A2 (en)	2003-03-26
HK1113057A1 (en)	2008-09-19
US20040019190A1 (en)	2004-01-29
IL193619A0 (en)	2009-02-11
JP2006137764A (en)	2006-06-01
MXPA02011621A (en)	2004-05-17

Publication	Publication Date	Title
BE2014C009I2 (en)	2021-02-04
BE2013C060I2 (en)	2020-12-15
BE2012C026I2 (en)	2020-12-15
BE2010C018I2 (en)	2020-08-20
BE2010C019I2 (en)	2020-08-20
BRPI0112928B8 (en)	2021-05-25
AR028236A3 (en)	2003-04-30
IN192748B (en)	2004-05-15
BRPI0113372A8 (en)	2003-06-24
CH694022C1 (en)	2016-03-15
BR122012015772A2 (en)	2004-02-25
CN3141398S (en)	2000-03-08
CN3145854S (en)	2000-04-19
AU2000270908A8 (en)	2002-06-06
AU2000270757A8 (en)	2002-04-18
CN3133795S (en)	2000-01-05
CN3135489S (en)	2000-01-19
CN3135513S (en)	2000-01-19
CN3135640S (en)	2000-01-19
CN3135789S (en)	2000-01-26
CN3135930S (en)	2000-01-26
CN3136721S (en)	2000-02-02
CN3139849S (en)	2000-02-23
CN3140016S (en)	2000-03-01
AU2000267632A8 (en)	2001-08-23